Table 3.

Characteristic of included studies for long-term outcome

Author and year	Country	Design	Patients (and cohort by antiplatelet drug use)	Mean age (years)	Male sex (%)	Outcome measured	Length of follow-up	Results
D’Ascenzo et al. (2019)	25 cardiovascular centers across nine countries (InterTAK Registry)	Multicenter observational retrospective cohort study	1533 (aspirin at discharge: 1031; none: 502)	66.4 ± 13.1	9.8	MACCE	5 years	HR 1.11 (95% CI 0.78–1.58), p = 0.58
Piackova et al. (2018)	Austria	Observational retrospective cohort study	99 (44 aspirin alone, 44 DAPT for 12 months than aspirin, 11 none)	67.8	18.2	All-cause and cardiovascular mortality	5.9 years	CV mortality HR = 0.61; CI = 0.21–1.79, p 0.37; all-cause HR = 0.81; CI = 0.45–1.46, p = 0.49)
Abanador-Kamper et al. (2016)	Germany	Observational retrospective cohort study	72 (28 on monotherapy; 29 on DAPT; 2 on triple therapy; 4 on OAC + aspirin/clopidogrel; 9 none)	68.8	7	MACE	24 months and 36 months	Low MACE rate compared with existing data. 1 had a stroke on OAC; 1 recurrence in DAPT, 1 MI in monotherapy
Khalighi et al. (2016)	USA	Observational retrospective cohort study	12 (6 patients on aspirin, 4 on DAPT; 2 patients with none)	66	0	Death, cardio- shock, SCD, recurrence, re-hospitalization	8.3 ± 3.6 years	No difference
Cacciotti et al. (2012)	Italy	Observational retrospective cohort study	75 (19 were lost during follow-up, so 56, 83.9% on aspirin)	71.9	4	MACE	2.2 years	Both death and recurrence occurred in patients on aspirin

MACCE major adverse cardiovascular and cerebrovascular events, HR hazard ratio, CI confidence interval, DAPT dual antiplatelet therapy, CV cardiovascular, OAC oral anticoagulation, MACE major adverse cardiovascular events, MI myocardial infarction, SCD sudden cardiac death